Medical Devices: What Those Paying Are Saying
The Affordable Care Act is shifting the economic risks of care from the payors to the providers, and medtech companies will be forced to find new sales and distribution channels, new ways of defining clinical and economic benefit, and new offerings wrapped around devices to enhance both their clinical and economic value. At the IN3 meeting in October 2013, executives from both the payor and provider communities discussed how medtech companies should respond to these new dynamics.
You may also be interested in...
The company’s leadership team is “determined to transform Medtronic from being a primarily device provider today into the premier global medical technology solutions partner of tomorrow,” CEO Omar Ishrak said.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.